Почетна › Рак билијарног тракта › Тексас
Kliničke studije za Рак билијарног тракта u državi Тексас
26 studija za Рак билијарног тракта traži učesnike na lokacijama u državi Тексас.
Gradovi u državi Тексас
Zvanični tekst studije (na engleskom)
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
- The University of Texas MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1
Узраст 16 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07197554A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- The University of Texas MD Anderson Cancer Center, Houston
- NEXT Oncology, San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07458347A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT07020221D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
- Texas Oncology, Dallas
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06622057A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06760819CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
- Clinical Study Site, Austin
- Clinical Study Site, Dallas
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT07909031A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- University of Texas MD Anderson Cancer Center ( Site 0316), Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06428409A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Texas Oncology - West Texas, Amarillo
- Texas Oncology, P.A., Dallas
- Texas Oncology Gulf Coast, Pearland
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT06330064AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, Dallas
- Avenzo Therapeutics Recruiting Site, Houston
- Avenzo Therapeutics Recruiting Site, San Antonio
Тражи се учесникФаза 1/2
Узраст од 18 до 75 · Оба пола · Ажурирано 16. 10. 2026. · NCT07038343A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors
- Next Oncology Dallas /ID# 284346, Irving
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 16. 10. 2026. · NCT07807956Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- NEXT Oncology, San Antonio
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 15. 10. 2026. · NCT06239194Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- MD Anderson Cancer Center /ID# 255131, Houston
- Univ Texas HSC San Antonio /ID# 257708, San Antonio
- South Texas Accelerated Research Therapeutics /ID# 260404, San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 14. 10. 2026. · NCT06084481Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- Research Site, Dallas
- Research Site, Fort Worth
- Research Site, Houston
Тражи се учесникФаза 3
Узраст од 18 до 99 · Оба пола · Ажурирано 13. 10. 2026. · NCT06467357Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Start - Dfw, Fort Worth
- Oncology Consultants, Houston
- START - San Antonio, San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06293898AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
- Research Site, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 30. 9. 2026. · NCT06219941A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
- University of Texas Southwestern Medical Center (Site 104), Dallas
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 29. 9. 2026. · NCT07265674Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
- MD Anderson Cancer Center, GI Medical Oncology Dept, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 28. 9. 2026. · NCT05482893A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
- Research Site, Houston
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 28. 9. 2026. · NCT07221253Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Houston
Тражи се учесникФаза 2
Узраст од 18 до 130 · Оба пола · Ажурирано 23. 9. 2026. · NCT05489211CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
- MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 9. 9. 2026. · NCT06548412A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- The University of Texas, MD Anderson Cancer Center, Houston
- UT Health Mays Cancer Center, San Antonio
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 11. 8. 2026. · NCT05592626A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Baylor Scott & White Research Institute, Dallas
- University of Texas MD Anderson Cancer Center, Houston
- Baylor Scott & White Medical Center, Temple
Тражи се учесникФаза 2
Узраст 8 и старији · Оба пола · Ажурирано 27. 7. 2026. · NCT05503797This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
- NEXT Oncology, Austin, TX 78758
- NEXT Oncology, San Antonio
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 2. 4. 2026. · NCT06451497Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
- Houston Methodist Hospital Cancer Center, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 2. 4. 2026. · NCT05733598Ligufalimab and Cadonilimab in Advanced Liver Cancers
- University of Texas Southwestern Medical Center, Dallas
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 27. 2. 2026. · NCT06789848A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 11. 12. 2025. · NCT06943521Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.